DNL 919
Alternative Names: ATV-TREM2; ATV:TREM2 - SI; DNL-919; TAK-920Latest Information Update: 12 Oct 2023
At a glance
- Originator Denali Therapeutics Inc
- Developer Denali Therapeutics Inc; Takeda
- Class Antibodies; Antidementias
- Mechanism of Action TREM2 protein-stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease